PL
DNLI icon

Plancorp LLC’s Denali Therapeutics DNLI Stock Holding History

Plancorp LLC’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,900
Closed -$227K – 239
2021
Q2 		$227K Buy
+2,900
New +$179K 0.02% 205
2021
Q1 		– Sell
-3,333
Closed -$279K – 208
2020
Q4 		$279K Buy
+3,333
New +$201K 0.07% 165

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Plancorp LLC's DNLI Position: Q3 2021 in Review

Plancorp LLC sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 2,900 shares — an estimated $227K sold.

Plancorp LLC first reported a position in DNLI in Q4 2020 and held it in 2 quarters. The position peaked at $279K in Q4 2020. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Plancorp LLC reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Plancorp LLC sold 2,900 Denali Therapeutics shares in Q3 2021, an estimated $227K.
  • Plancorp LLC first reported a position in Denali Therapeutics in Q4 2020 and held it in 2 quarters.
  • Plancorp LLC's Denali Therapeutics position peaked at $279K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Plancorp LLC's 13F filing for Q3 2021, filed 15 Nov 2021.